DOCS logo

DOCS
Doximity Inc

4,184
Mkt Cap
$3.67B
Volume
1.18M
52W High
$76.51
52W Low
$17.15
PE Ratio
19.76
DOCS Fundamentals
Price
$19.83
Prev Close
$19.39
Open
$19.25
50D MA
$23.52
Beta
1.17
Avg. Volume
3.08M
EPS (Annual)
$0.9849
P/B
3.73
Rev/Employee
$732,798.86
$3,899.40
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is...
News Placeholder
More News
News Placeholder
Doximity to Present at the William Blair 46th Annual Growth Stock Conference
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:40 p.m. Central Time. About Doximity Founded in 2010...
News Placeholder
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
News Placeholder
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
News Placeholder
DOCS vs. HIMS: Which Stock Is the Better Value Option?
DOCS vs. HIMS: Which Stock Is the Better Value Option?
News Placeholder
DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
Doximity teams with Aledade to bring AI-powered documentation and clinical search tools into physician workflows and value-based care settings.
News Placeholder
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
News Placeholder
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OPRX cuts 2026 revenue view to $95-$100M as MFN pricing disruption and macro uncertainty squeeze budgets - will pressures ease?
News Placeholder
Down 25.7% in 4 Weeks, Here's Why Doximity (DOCS) Looks Ripe for a Turnaround
Doximity (DOCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
News Placeholder
Doximity Enters Oversold Territory (DOCS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available